It is a strange and explosive book which presents in exclusivity Express previews. Medications, side effects: death, John Virapen, published by the Cherche Midi under the patronage of Professor Philippe Even, a book is strange because it is already published in Germany in 2008, then Britain, in Sweden and in other countries, without causing a large mdiatique curiosity or raise scandal. Explosive, it is because it prtend unveil the terrible workings of markets the medicinal product: "invention" of conditions to sell remdes, clinical trials biaiss intense lobbying auprs of the authorities and, of course, prescribing doctors. . .
Today install Malm, John is Virapen presents as former CEO of Eli Lilly and Company in Sweden. The laboratory has confirmed that t Lilly employee in Denmark and Sweden, from 1979 1988, but accuracy of by the mouth of his mdicale Director for France and Benelux, Dr. Elena Perrin, that "in the 1980s, Lilly has no subsidiary in Sweden, but only a representation office at least, that is – say officials in the field mdicor latory and no autonomy Financire ".
Lilly also said that Virapen boyfriend left the group in October 1988, while in Sweden the authorization fluoxtine dates only from 1995, or the validation requirements of this Molcule, better known under the name Prozac is one of the major attacks of the author. "The statements of John Virapen concerning facts which took place when he was at Lilly employee in Sweden in the 1980s have no basis, says Dr. Perrin. Had they exist and were t known Lilly, they have been subject to disciplinary PROCEDURAL against John Virapen after enqute. allgations on His Lilly give a totally false picture of the group and its practices. "the reader to judge. . .
I began to investigate Professor Z. more prs. He loved sailing. I bought a book on sailing. I found the type of yacht that made me possdait and deliver information to the office. I have nearly the tudiai. I examined the photos of the yacht. I closed my eyes, propped me in my chair and imagined Professor Z. rising edge, the aerodynamic line of the boat, the engine noise dmarre, etc.. [. . . ] I called Professor Z. and I managed to invite dinner. I was not too apprhension, but I can not say that I had no fear, a fright.
It is as if we rode in scene. I learned to focus in these cases on the things that matter REALLY on the goal I m'tais fix. The trick is not to rush like a bull – but despite all drag a foot in the door. It must seem to behave naturally. Played a factor in my favor: I did not like Professor Z. tural sympathy makes it more difficult manipulations. We do not like picking a person that apprcie. We do not want to make someone you love cross the borders of lgalit.
I paid the bill, without trying to go further, but I soon invite again. "A dinner is always a good idea," he said. This time I was ready fair play I did not know if it would be before or after the meal. I orient the conversation, once again, on fluoxtine. "Do not get me wrong, but I know that you are charged for our case the Commission health." Professor Z. did was not shocked. He just smiled and ordered another glass of wine.
"Seven years is a very long," I said in a tone dtach [The author alludes hard with the procedure of authorization. ] Professor Z. nodded to the head, always pench on his glass of wine, and continued smiling. I changed the subject back to sailing. He seemed rather pleased and invited me on his yacht. I asked him what it would take to abrger a bit this deadline of seven years and, if possible, upwind, as they say in navigation. "A chevronn browser can bypass the coast even more steep" is dfendit it. "But navigate on land, voil would be impossible even for the best sailor," I rtorquai.
The Copenhagen office contrlait throughout the Nordic area. The next day, I called the director Copenhagen, I told him it would cost 100,000 crowns for a quick authorization Sweden. A At the time, it reprsentait about 20,000 dollars. I told him to name the chque should be denominated and would be cashed Copenhagen, Denmark, for tax reasons, to avoid the impt. The director understood very well that. The transfer does not apparatrait in our accounts but would probably consign Geneva and registered under "Fellowship". B. My manager told me that Copenhagen should, however, talk to Chief Financial Officer. The Copenhagen office of the Geneva consultations. It took twenty-four hours. Then I call reus Copenhagen: "John, do whatever you think is necessary."
It would be necessary to create an independent entrance institution having access all available information on clinical effects. [Note Philippe Even (NPE): "The key issue of open access all folders firms is full DBAT two years in the United States, England and Switzerland Firms there?. still refuse radically in the name of industrial property and hold on tight, to protect the anonymity of the patients who participated in the trials, anonymity lev aisment by computer. But see, this is for you defend you, the patient, as firms refuse to open their files! You should thank them. "] [. . . ]
[. . . ] Nothing obliges firms to make public the results of clinical trials termins. Yet it is in these tests failure that can find information about the effectiveness and risks of ral molecules and not in studies arranges after sudden liss es, biased, Lagues, slectionnes, faonnes by pharmaceutical industries.
Firms impose the obligation to produce compltes information not only on termins clinical trials they publish, but also interrupted clinical trials or those that do not publish after having finished s because they contain information that would make it public and their prjudiciables of scientists who give their rivals could benefit from a medicine to produce more effective or less risk. [NPE: "There s an squestration knowledge damaging private and public research Entire everything that stigmatize ESPECIALLY five major studies Lancet 8 and 15 January 2014."]
The advertising on medicines or imaginary diseases should be prohibited, including that s'tale here and, of years before the release of the medicinal product. [The purpose of advertising is] to put pressure on patients, families, and sometimes parents and educators (eg in the case of Daha the [hyperactivity]). These are so sick themselves and sometimes their finances associations backstage industry exercising pressure on government authorities to facilitate or accelerate the authorizations on the market. [. . . ]
There is no justification, under any pretext, to hover the risk of death on anyone. However, the pharmaceutical industry and even the health authorities of reason and accept otherwise fatal risks of 0.01 and even 0.1% under what they call the analysis of b nfice risk, where risk is consistently under-rated and efficiency instead survalue. [. . . ] A risk of 0.01%, this does not seem very important, but these medications are often prescribed hundreds of thousands, even millions of patients, then 1 after the comma is often found before and it is 10, 100, 1000patients dying around the world. 0.01% of 1 million is 100 deaths every year! "One death is a tragedy, a million deaths is a statistic," said Lenin.
More on this topic online-sportangebote.eu